Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms

JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In SET2 cells, AURKA and A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Lima, Keli, Carlos, Jorge Antonio Elias Godoy, Alves-Paiva, Raquel de Melo, Vicari, Hugo Passos, Souza Santos, Fábio Pires de, Hamerschlak, Nelson, Costa-Lotufo, Leticia Veras, Traina, Fabiola, Machado-Neto, João Agostinho
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6616334/
https://ncbi.nlm.nih.gov/pubmed/31289316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-46163-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados